Medpage
Published: Nov 14, 201WASHINGTON -- The FDA has approved the angiogenesis inhibitor
bevacizumab (Avastin) for use in combination with paclitaxel to treat
platinum-resistant recurrent #ovarian cancer.
The approval was
based on results of an international, phase III, randomized trial to
compare paclitaxel alone with paclitaxel plus bevacizumab. Known as AURELIA,
the trial involved 361 women whose ovarian cancer had recurred less
than 6 months after their most recent platinum-based chemotherapy
regimen.
The trial had a final endpoint of progression-free
survival (PFS), and the results demonstrated a 62% reduction in the
hazard for progression or death in patients who received bevacizumab.........
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.